Principal Scientist/Scientific Director, protein drug discovery and development.

Y-mAbs Therapeutics is establishing an in-house focus area of protein engineering within the CMC governance area. The focus area of protein engineering will support our growing pipeline of future product candidates. We are therefore looking for a candidate with both a strong scientific knowledge in the area and with an entrepreneur mindset to lead and grow this focus area.

Y-mAb Therapeutics Inc. has a R&D Scientific Lab located in Nutley, NJ which currently leads the identification of new targets as well as lead selection process under the governance and responsibility of the CSO. The candidate will play a key role supporting the future lead candidate selection process moving identified targets to final development candidates. This encompass designing and directing the first antibody campaigns, based on immunizations or available sequence information, and collaborate on an optimal screening strategy throughout the lead selection process, based on structural and biochemical insight. The candidate is responsible for leading the biochemical and biophysical characterization to secure that the initial and lead candidates are designed and expressed with the desired product attributes to secure mode of action, physical and chemical stability as well as robust manufacturability.

The position will be anchored in our CMC development located in Hoersholm, Denmark as a new focus area and will operate as link between R&D Science, Translational Medicine group and CMC development. It is expected that the chosen candidate will add protein chemistry and engineering expertise to the lead selection process governed by Y-mAbs R&D Scientific Lab and can drive the protein engineering development and growth of this new focus area to support the diverse Y-mAbs development portfolio including mono- and bispecific antibody formats and novel protein-based constructs.

The execution of the lead candidate development will be done in collaboration with Y-mAbs R&D Scientific Lab and external CROs, and it will be the responsibility of the candidate to identify and oversee the right CROs for protein engineering campaigns.

A key aspect of this role is the ability to add protein chemistry knowledge to design the optimal drug candidate screening and characterization plan in the context of the specific target biology. The candidate must be able to directly steer and influence discussions and decisions related to the development of an appropriate drug modality, while being able to collaborate and work closely with scientific leads across all therapeutics areas to drive the protein optimization and development tasks within agreed timeline supporting the timely progress of pipeline projects.

Most of the current Y-mAbs pipeline is based on mAb technology, and the candidate is expected to be experienced in mAb biology, including antibody antigen interactions.

Qualifications:

- Extensive experience in engineering and characterization of protein and antibody variants as clinical leads
- In depth knowledge with protein design, engineering, and expression
- Experience with therapeutic protein drug discovery and development
- Experience with analytical set-up for selection of product candidates
- Experience in structure/function-based techniques and protein design tools
- Experience with evaluation and reduction of potential immunogenicity of therapeutic proteins
- Management of external collaboration and experience in working with CROs
- Proven track record of cross-functional collaboration with leading functional teams, and managing core team resources
For more details about the job or our company, please contact Tore Søderblom, Senior Director, CMC Development on +45 5388 0988. Please note that all applications must be submitted in English and will be treated confidentially.

You can apply for the position by sending an email to HR@ymabs.com. Please mark your application with Job ID no. 1047.

Y-mAbs Therapeutics A/S is a Danish affiliate of Y-mAbs Therapeutics Inc., which is located in New York. Our mission is to discover, develop and deliver novel antibody therapeutics for the treatment of both pediatric and adult cancer patients.

Please access the company web site www.ymabs.com for more information regarding the company and our development projects.